Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by an educational grant from Daiichi Sankyo.

Leveraging Novel Antibody-Drug Conjugates in a World of Evolving Treatment Paradigms: A Pan Tumor Perspective

Release Date: November 30, 2020
Expiration Date: November 30, 2021

Activity Overview

This online, on-demand virtual symposium brings together oncology thought leaders from around the globe to discuss the evolving world of antibody-drug conjugates (ADCs) in cancer treatment. The targeting of tumor cell surface antigens remains a key therapeutic approach in oncology. ADCs combine the specificity of a tumor-targeting antibody with a cytotoxic payload. Several ADCs have been approved, with additional agents in development that target an expanding range of tumor antigens, including HER2, HER3, and Trop-2, as well as several other molecules. In this educational program, these experts discuss the expanding therapeutic options provided by ADCs, how to optimize the use of these agents in clinical practice, and best approaches for biomarker assessment and management of adverse events.

This educational activity is an archive of the live, virtual symposium held on November 21, 2020.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Daiichi Sankyo.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.


Target Audience

This educational program is directed toward a global audience of medical oncologists, pathologists, and fellows interested in the treatment of cancer. Nurse practitioners, physician assistants, nurses, pulmonologists, and other health care professionals involved in the treatment and management of patients with cancer will also be invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Determine the rationale underlying the use of antibody-drug conjugates in solid tumors
  • Apply optimized HER2-testing strategies to facilitate molecular characterization of solid tumors
  • Evaluate ongoing clinical trials and evolving data sets for novel antibody-drug conjugate targeted therapies across solid tumors
  • Integrate novel antibody-drug conjugate approaches into care for patients with a variety of solid tumor types

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Faculty

Masakazu Toi, MD, PhD
Masakazu Toi, MD, PhD
Director, Breast Cancer Unit
Kyoto University Hospital
Professor of Breast Surgery
Graduate School of Medicine
Kyoto University
Kyoto, Japan

Disclosures: Grant Research Support: AFI Technology, Astellas Pharma, AstraZeneca, Chugai Pharmaceutical Co., Eisai, GL Sciences, Japan Breast Cancer Research Group, Kayaku Advanced Materials, Kyowa Kirin, Luxonus, Nippon, Shimadzu Corporation, Taiho Oncology, Yakult; Consultant: Athenex Oncology, Bertis, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly & Company, Kyowa Kirin, Terumo Corporation; Speakers’ Bureau: Pfizer.

Maurice Pérol, MD
Maurice Pérol, MD
Medical Oncologist
Léon Bérard Cancer Center
Lyon, France

Disclosures: Grant Research Support: Hoffmann-La Roche, AstraZeneca, Takeda Pharmaceutical Company, Boehringer lngelheim, Chugai Pharmaceutical Co.; Consultant: Eli Lilly & Company, Hoffman-La Roche, AstraZeneca, Pfizer, Boehringer lngelheim, Bristol Myers Squibb, Merck Sharp & Dohme, Takeda Pharmaceutical Company, Novartis Pharmaceuticals; Gritstone Oncology; Speakers’ Bureau: Eli Lilly & Company, Hoffmann-La Roche, AstraZeneca, Pfizer, Amgen, Boehringer lngelheim, Bristol Myers Squibb, Merck Sharp & Dohme, Takeda Pharmaceutical Company, Novartis, Illumina, Chugai Pharmaceutical Co.

Josep Tabernero, MD, PhD
Josep Tabernero, MD, PhD
Head, Medical Oncology Department
Vall d’Hebron University Hospital
Director, Vall d’Hebron Institute of Oncology
Vall d’Hebron Hospital
Professor of Medicine
Universitat de Vic, Universitat Central de Catalunya
Barcelona, Spain

Disclosures: Consultant: Array Biopharma, AstraZeneca, Bayer Healthcare, BeiGene, Biocartis, Foundation Medicine, Boehringer Ingelheim, Chugai Pharmaceutical Co., Hoffmann-La Roche, Genentech, Genmab A/S, HalioDX SAS, Halozyme Therapeutics, Imugene, Inflection Biosciences, Ipsen Pharma, Kura Oncology, Eli Lilly & Company, Merck Sharp & Dohme, Menarini Group, Merck Serono, Merrimack Pharmaceuticals, Merus, Molecular Partners, Novartis Pharmaceuticals, Peptomyc, Pfizer, Pharmacyclics, ProteoDesign SL, Rafael Pharmaceuticals, Roche Diagnostics, Sanofi, SeaGen, Seattle Genetics, Servier Laboratories, Symphogen, Taiho Oncology, VCN Biosciences.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.


Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
   1234
567891011
12131415161718
19202122232425
262728293031
Filter By